可行性即服务

Expert-led, data-driven feasibility tode-risk trial design and execution Trial design and site selection decisions aretoo costly to get wrong. Sponsors today face escalating challenges: $500Kin lost salesdaily3fromdelays months longerfor trial timelines,2020–242 increasein protocol amendmentssince 20151 1New Benchmarks on Protocol Amendment Practices, Trends and their Impact on Clinical Trial Performance2https://www.statista.com/statistics/1419920/biopharma-clinical-trial-cycle-time/3New Estimates on the Cost of a Delay Day in Drug Development Our Solution:Feasibility as a Service (FaaS) FaaS is anexpert-led, data-drivenassessment that helps determine protocolviability, site selection strategies, recruitment plans, and mid-trial rescuedecisions. Powered by Citeline’s gold-standardSitetrove and Trialtrovetools,our next-generation feasibility isnow delivered as a serviceanchored in anindependent and objectiveperspective to guide confident decisions. Withdynamic, decision-ready outputs, we help sponsors and theirdevelopment partnersde-risk design,adapt in real time, and keepstudies on track without adding operational burden. Flexible Feasibility forAny ChallengeandAny Phase Referral network strategyRecruitment optimizationPatient identification High-level planning supporting go/no go decisionsIdeal country and site selectionCRO pressure testing Our feasibility approach combines aphased process with rich, connected data Whether your trial is in earlyplanning stages or enrolling,FaaS services offer analysisat multiple stages forstrategic decision makingand outputs. Review analysis and/or recommendationsbased on experience,patient counts, trialcapacity, and more. ProprietaryPerformance ... andmore US LivesLab Data OUS LivesEHR/EMRData US LivesClaims Data Overview Case Study Outcome A leading CRO engaged Citeline to help assess underperformance in a globalPhase III RCC trial. Through our analysis we: These insightshelped the CROsecure the rescueengagement andare now guidingthe post-rescuemitigationstrategy. FeasibilityRescue fora Phase IIIOncology Trialin Renal CellCarcinoma(RCC) Identified that in9 outof 10selected countries,site-level enrollmentlagged by anaverage of70%below benchmarkrates, based on recentRCC trial performance Provided alist of120+recommendedinvestigators withhigh potential tosupport rescueefforts Recommendedadditionalcountries with>5xhigher enrollmentpotential vs. currentselected countries Citeline.The data, the expertise,the independence you need to moveyour trial forward with confidence. Learn more atCiteline.com